National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
NCI Drug Dictionary

anti-CD30 monoclonal antibody XmAb2513
A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:XmAb2513

Previous:anti-CD20 monoclonal antibody R7159, anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1), anti-CD30 monoclonal antibody MDX-1401
Next:anti-CD33 monoclonal antibody-DM4 conjugate AVE9633, anti-CD37 single-chain polypeptide TRU-016, anti-CD38 monoclonal antibody, anti-CD45 monoclonal antibody, anti-CD45 monoclonal antibody AHN-12